Jason Hoitt
Corporate Officer/Principal bei STOKE THERAPEUTICS, INC.
Profil
Jason Hoitt is currently the Chief Commercial Officer at Stoke Therapeutics, Inc. He previously held positions as the Head-US Sales at Sarepta Therapeutics, Inc. from 2013 to 2017, Vice President & Head-US Sales at Insmed, Inc. in 2017 to 2018, Chief Commercial Officer at Dova Pharmaceuticals, Inc. from 2018 to 2019, and Chief Commercial Officer at Provention Bio, Inc. from 2020 to 2023.
Mr. Hoitt obtained his undergraduate degree from the College of the Holy Cross (Massachusetts) in 1999.
Aktive Positionen von Jason Hoitt
| Unternehmen | Position | Beginn |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 15.04.2024 |
Ehemalige bekannte Positionen von Jason Hoitt
| Unternehmen | Position | Ende |
|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 01.06.2023 |
| DOVA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 12.11.2019 |
| INSMED INCORPORATED | Vertrieb & Marketing | - |
| SAREPTA THERAPEUTICS, INC. | Vertrieb & Marketing | 01.05.2017 |
Ausbildung von Jason Hoitt
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
